

ONCOLOGY GENETIC TESTING REQUISITION

All Information Must Be Completed Before Sample Can Be Processed

PATIENT INFORMATION

Patient Name: _____, _____, _____
Last First MI

Address: _____

Home Phone: _____ MR#: _____

Date of Birth: _____/_____/_____ Gender: Male Female

INDICATIONS/DIAGNOSIS/ICD-9 CODE

- | | | | |
|---|---|--|---|
| <input type="checkbox"/> Acute Myelogenous Leukemia | <input type="checkbox"/> Glioma | <input type="checkbox"/> Langerhans cell histiocytosis (LCH) | <input type="checkbox"/> Pancytopenia |
| <input type="checkbox"/> Acute Promyelocytic Leukemia | <input type="checkbox"/> Hodgkin lymphoma | <input type="checkbox"/> Malignant melanoma | <input type="checkbox"/> Polycythemia Vera (PV) |
| <input type="checkbox"/> Adenopathy | <input type="checkbox"/> Leukocytosis | <input type="checkbox"/> Medulloblastoma | <input type="checkbox"/> Sarcoma |
| <input type="checkbox"/> Anemia | <input type="checkbox"/> Leukopenia | <input type="checkbox"/> Monoclonal gammopathy | <input type="checkbox"/> Thrombocytopenia |
| <input type="checkbox"/> Burkitt Lymphoma | <input type="checkbox"/> Leukemia | <input type="checkbox"/> Multiple Myeloma | <input type="checkbox"/> Thrombocytosis |
| <input type="checkbox"/> Chronic Myelogenous Leukemia | <input type="checkbox"/> Lung cancer | <input type="checkbox"/> Myelodysplastic syndrome or disease (MDS) | <input type="checkbox"/> Wilms tumor |
| <input type="checkbox"/> Chronic Lymphocytic Leukemia | <input type="checkbox"/> Lymphoma | <input type="checkbox"/> Myeloproliferative disease (MPS or MPD) | <input type="checkbox"/> Other _____ |
| <input type="checkbox"/> Colorectal cancer | <input type="checkbox"/> Lymphocytosis | <input type="checkbox"/> Neutropenia | _____ |
| <input type="checkbox"/> Ewing sarcoma | <input type="checkbox"/> Lymphoproliferative disorder | <input type="checkbox"/> Non-Hodgkin Lymphoma (NHL) | _____ |

BILLING INFORMATION (Choose ONE method of payment)

REFERRING INSTITUTION

Institution: _____

Address: _____

City/State/Zip: _____

Accounts Payable Contact Name: _____

Phone: _____

Fax: _____

Email: _____

COMMERCIAL INSURANCE*

Insurance can only be billed if requested at the time of service.

Policy Holder Name: _____

Gender: _____ Date of Birth _____/_____/_____

Authorization Number: _____

Insurance ID Number: _____

Insurance Name: _____

Insurance Address: _____

City/State/Zip: _____

Insurance Phone Number: _____

ETHNIC/RACIAL BACKGROUND (Choose All)

- | | |
|--|--|
| <input type="checkbox"/> European American (White) | <input type="checkbox"/> African-American (Black) |
| <input type="checkbox"/> Native American or Alaskan | <input type="checkbox"/> Asian-American |
| <input type="checkbox"/> Pacific Islander | <input type="checkbox"/> Ashkenazi Jewish ancestry |
| <input type="checkbox"/> Latino-Hispanic _____
(specify country/region of origin) | |
| <input type="checkbox"/> Other _____
(specify country/region of origin) | |

REFERRING PHYSICIAN

Physician Name (print): _____

Address: _____

Phone: (_____) _____ Fax: (_____) _____

Email: _____

Genetic Counselor/Lab Contact Name: _____

Phone: (_____) _____ Fax: (_____) _____

Email: _____

_____ Date: ____/____/____

Referring Physician Signature (REQUIRED)

SAMPLE/SPECIMEN INFORMATION

Has patient received a bone marrow transplant? Yes No

If yes, date of bone marrow transplant _____

Percent engraftment _____

Note: For post-transplant patients, we accept pre-transplant samples or post-transplant skin fibroblasts **ONLY** (blood, saliva, and cytobrushes are not accepted). Culturing of skin fibroblasts is done at an additional charge.

Specimen Date: _____ Time: _____

DRAWN BY: _____

*Phlebotomist must initial tube of specimen to confirm sample identity

DISEASE STATUS:

New diagnosis Remission Relapse E(COG) study COG patient

SPECIMEN TYPE — SEE PAGE 3 FOR SPECIMEN REQUIREMENTS

Bone marrow Oncology blood Lymph node

Formalin fixed paraffin embedded tissue Touch prep Smear

Estimated percent of tumor in sample: _____

Solid tumor (specify): _____ If in media, type: _____

Estimated percent of tumor in sample: _____

Other: _____ WBC _____ % Blasts _____

TEST(S) REQUESTED

SEE PAGE 3 FOR SPECIMEN AND TEST DETAILS

Cytogenetic Chromosome and Microarray Analysis

Oncology Chromosome Analysis

Constitutional (blood) Chromosome Analysis

Oncology Microarray

[Additional 3 mL blood or bone marrow (NaHep) if ordered without chromosomes] — % Tumor: _____

Medulloblastoma Methylation Array (Microarray SNP)

Fresh tumor preferred, FFPE optional

Medulloblastoma Subgrouping & CNV Analysis**

Medulloblastoma Subgrouping ONLY

Medulloblastoma CNV Analysis ONLY**

FISH

(Additional FISH probes available. See page 3 for details.)

t(9;22) [*BCR/ABL1*]

11q23 [*KMT2A*]

X/Y [Opposite sex BMT]

t(15;17) [*PML/RARα*]

Other (please call lab) _____

Hematologic FISH Panels

(All probes available individually. Please see page 3 for panel descriptions)

ALL Hyperdiploid

Fanconi anemia

ALL Risk Stratification

Multiple myeloma

Ph-like ALL

MDS

AML

MPD

APL

SDS

Burkitt Lymphoma

Large cell NHL

CLL

Small cell NHL

Double Hit Lymphoma

Combined NHL

Eosinophilia

T-Cell Lymphoma/Leukemia

Molecular Genetic Analysis (RNA assays)

Samples must be received within 24 hours of collection.

BCR/ABL - QUANTITATIVE (p210)

BCR/ABL - QUANTITATIVE (p190)

BCR/ABL - RT-PCR (QUALITATIVE)

PML/RARα - RT-PCR

Molecular Genetic Analysis (DNA assays)

Samples must be received within 48 hours of collection.

JAK2 QUANTITATIVE (V617F)

PTEN sequencing

Bone marrow engraftment (BME) by STR (Same sex donor & recipient)

Pre-transplant host sample

Post transplant sample

Donor sample

WBC sub-populations engraftment study*

STR (same sex)

X/Y FISH (opposite sex)

Cell Separation (for non-engraftment testing)*

*You **MUST** call the **GENETICS LAB** at **513-636-4474** to schedule this test prior to sample submission.

Non-Hematologic Genetic Analysis

BRAF (7q34) **FISH** — (Glioma) — include 2 FFPE slides and 1 marked H & E slides

BRAF full gene sequence analysis (Glioma, colon lung, melanoma) —

%Tumor: _____

BRAF V600E by real-time PCR (**FFPE NOT ACCEPTED**)

(colon, lung, melanoma) — % Tumor: _____

BRAF (V600E) mutation only (Langerhans cell histiocytosis, colon,

lung, melanoma) — % Tumor: _____

MAP2K1 full gene sequence analysis (Langerhans cell histiocytosis, colon,

lung, melanoma) — % Tumor: _____

Non-Hematologic FISH Panels

Fresh tumor or FFPE slides (must include 1 marked H & E slide with FFPE)

Ependymoma FISH Panel

High-Grade Glioma FISH Panel

Low-Grade Glioma FISH Panel

Lung Cancer FISH Panel

Medulloblastoma FISH Panel

Melanocytic Tumor FISH Panel

Pilocytic Astrocytoma FISH Panel

ADDITIONAL INFORMATION

SPECIMEN REQUIREMENTS

Cytogenetic Analysis (Chromosome, FISH, and Microarray analysis):

3 mL blood or bone marrow (NaHep)

Chromosome analysis
Cell culture only
FISH probes and FISH panels

3 mL blood or bone marrow (EDTA)

Oncology microarray

Fresh Tumor or Lymph Nodes (1cm³ in sterile saline or sterile transport media)

Chromosome analysis
Cell culture
FISH probes and FISH panels

Molecular Genetic Analysis (RNA Assays): 5-10 mL blood or 3–5 mL bone marrow (EDTA) — Samples must be received within 24 hours of collection.

BCR/ABL — Quantitative (p210), *BCR/ABL* — Quantitative (p190), *BCR/ABL* — Qualitative, *PML/RAR α* — Quantitative

Molecular Genetics Analysis (DNA Assays): 3 mL bone marrow or blood (EDTA) — Samples must be received within 48 hours of collection.

JAK2 Quantitative (V617F), *PTEN* Seq, Bone marrow engraftment by STR, WBC sorted sub-populations engraftment study (by STR or FISH)

Non-Hematologic Genetic Analysis:

BRAF full gene sequencing, *BRAF* (V600E) mutation only analysis and *MAP2K1* full gene sequencing:

3 mL blood or bone marrow (EDTA), 1 cm³ fresh tumor or 10 formalin fixed paraffin embedded (FFPE) tissue scrolls. Please send additional scrolls (if possible) for extremely small tissue samples.

BRAF (V600E) by real-time PCR gene sequencing:

3 mL blood or bone marrow (EDTA) or 1 cm³ fresh tumor. FFPE is NOT an acceptable sample type for real-time PCR gene sequencing of *BRAF*.

FISH (Fluorescence In Situ Hybridization)

NOTE: All FISH probes are available for individual testing

Hematologic FISH Panels — 3 mL blood or bone marrow (NaHep)

- ALL Hyperdiploid: trisomy 4, 10, 17
- ALL Risk Stratification: 4, 10, 17, t(1;19), t(12;21), t(9;22), *KMT2A*
- Ph-like ALL: *CRLF2*, *ABL2*, *PDGFRB*, *CSF1R*, *JAK2*, *ABL1*, *EPOR*
- AML: t(8;21), *KMT2A*, inv(16)
- APL: t(15;17), *RAR α*
- Burkitt Lymphoma: t(8;14), *MYC*
- CLL: 13q14.3, 13q34, 12 centromere, *ATM*, *TP53*
- Double Hit Lymphoma: *BCL6*, *MYC*, t(8;14), t(14;18)
- Eosinophilia: 4q12, *PDGFRB*, *FGFR1*, *CBFB*
- Fanconi Anemia: 1q25, 3q27, mono 7 / del(7q)
- Multiple Myeloma (CD138+): 1p32.3/1q21, t(4;14), t(11;14), monosomy 13/del 13q, t(14;16), t(14;20), *TP53*
- MDS: mono 5/del 5q, mono 7/del 7q, tri 8, del (20q)
- MPD: 4q12, *PDGFRB*, *FGFR1*, *BCR/ABL1*

- SDS: mono 7/del 7q, tri 8, del (20q)
- Large cell NHL: t(11;14), t(14;18), *TP53*, *BCL6*, *ALK*
- Small B-cell NHL: t(11;14), t(14;18), 18q21 (*MALT1*), *CLL* Panel
- Combined NHL: (large and small cell panels)
- T-Cell Lymphoma: *TRA/TRD*, *TRB*; *TRG*, *BCR/ABL1*, *KMT2A*

Non-Hematologic FISH Panels — 4-8 FFPE slides cut to 4 micron thickness and 1 marked H & E slide** — Fresh Tumor (1cm³)

- Ependymoma: *ABL2*, *CDKN2A*, *C11orf95*, *RELA*
- High-Grade Glioma: *PDGFRA*, *CDKN2A*, *NTRK2*, *MYCN*
- Low-Grade Glioma: *TP73/ABL2*, *FGFR1*, *MYB*, *BRAF*, *MYBL1*
- Lung Cancer: *ALK*, *ROS1*, *MET*, *RET*
- Medulloblastoma: *MYB*, *LIS1/RAR α* , *MYC*, *MYCN*
- Melanocytic Tumor: *RREB1*, *MYC*, *CDKN2A*, *CCND1*
- Pilocytic Astrocytoma: *BRAF*, *CDKN2A**

**For each probe ordered, send 2 unstained slides with one section cut to 4 micron thickness and mounted on a charged slide. Blocks are also accepted for processing.*

**Pilocytic Astrocytoma FISH Panel only needs 2-4 FFPE slides and 1 marked H&E slide*

Methylation Array Specimen Options:

1. Fresh Tumor Tissue (Preferred Specimen Type): Send 10–25 mg (1cm³) of STERILE tumor tissue in STERILE saline or transport medium (RPMI)
 - a. Unacceptable Fresh Tumor Conditions: Specimen placed in formalin or non-sterile container.
 - b. Store at room temperature (if storing overnight, please **REFRIGERATE**). Use overnight shipping (protect from temperature extremes, no ice)
2. Formalin Fixed Paraffin Embedded Tissue (FFPE) (Optional)**: A representative FFPE block or 10 unstained FFPE slides and 4 scrolls (2 eppendorf tubes with 2 scrolls each) with a tumor surface area of up to 250mm².
 - a. If a pathology evaluation has already been performed on the sample, send a copy of the pathology report and include any additional IHC or molecular testing that might have been performed.
3. DNA (Optional)**: If DNA sample is available, please send 1ug DNA (max volume 90uL). DNA must have been extracted in a CLIA certified laboratory.

****ONLY MYC-N (2p24.3) amplification, GLI2 (2q14.2) amplification, Monosomy 6, MYC (8q24.21) amplification, 10q loss, Monosomy 11, 17p loss, 17q gain and isochromosome 17q will be reported for CNV Analysis performed on Formalin Fixed Paraffin Embedded (FFPE) tissue or DNA that was originally extracted from a FFPE sample.**

For any questions about specimen requirements, please call our laboratory at (513) 636-4474.

ADDITIONAL INFORMATION, CONTINUED

For Chromosome Breakage Study for Fanconi Anemia - Please see Fanconi Anemia requisition
(www.cincinnatichildrens.org/cytogenetics or call 513-636-4474)

SHIPPING INFORMATION

Local courier is available; please call 513-636-4474 for information.

Shipping:

For samples that arrive **Monday–Saturday:**

Cincinnati Children's
Cytogenetic and Molecular Laboratories
3333 Burnet Ave.
TCHRF 1042
DOCK 5
Cincinnati, OH 45229-3039

BILLING INFORMATION

*** PLEASE NOTE:**

- We will not bill Medicaid, Medicaid HMO, or Medicare except for the following: CCHMC Patients, CCHMC Providers, or Designated Regional Counties.
- If you have questions, please call 1-866-450-4198 for complete details.

Patient signed completed ABN

Medical Necessity Regulations: At the government's request, the Molecular Genetics Laboratories would like to remind all physicians that when ordering tests that will be paid under federal health care programs, including Medicare and Medicaid programs, that these programs will pay only for those tests the relevant program deems to be (1) included as covered services, (2) reasonable, (3) medically necessary for the treatment and diagnosis of the patient, and (4) not for screening purposes.